This link takes you to Probity Medical Research's website dedicated to patients called ResearchTrials.org. You will be re-directed in five seconds. If you are not re-directed click here.
Since 1995, Probity Medical Research (PMR) has been providing support for clinical research sites from our head office in Waterloo, Ontario, Canada. During this time, PMR has grown and now has research facilities in Australia, Canada, and the United States. Learn more. |
| ||||
| Showing 8 entries. | |
|---|---|
New Technology is Game-Changer for Suprapubic CatheterizationBIGFORK, Montana and KITCHENER Ontario, Canada, Swan Valley Medical, Incorporated, together with St. Mary’s General Hospital announced that the T-SPeC® Surgical System was used in its first live human clinical cases on August 15, 2012, for the treatment of chronic urinary retention and to evaluate patient comfort and improved safety. Dr. Michael Freeman is Currently Conducting Clinical Trials for Psoriasis in Benowa, Queensland, AustraliaDermatolgoist Dr. Michael Freeman is among many clinical trial sites in Australia beginning new clinical trials for psoriasis this year. Probity Medical Research Welcomes Dr. Mark Lomaga and Dr. Firouzeh NiakosariProbity Medical Research Inc. (PMR), a leading provider of clinical research support services, welcomes Dr. Mark Lomaga, BScPhm, PhD, MD, DABD, FRCPC and Dr. Firouzeh Niakosari, MD, FCAP, FRCPC (Pathology and Dermatology) and their dermatology research team in Mississauga, Ontario, Canada. Probity Medical Research Welcomes Australian Dermatologist Dr. Diana RubelProbity Medical Research Inc. (PMR), a leading provider of clinical research support services, welcomes Dr. Diana Rubel, MB BS, Dip Paeds, M Med, FACD to PMR's international network of Dermatology clinical trial sites. Probity Medical Research Inc. Appoints R. Blair Egerdie, MD, FRCSC, Director of UrologyClinical Research Company, Probity Medical Research Inc. (PMR) announced today the appointment of Dr. R. Blair Egerdie as the Director of Urology, effective October 17, 2011. Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasisNovartis has announced positive results from three Phase II trials showing that AIN457 (secukinumab) produced a quick and significant improvement of symptoms in patients with moderate-to-severe plaque psoriasis. Probity Medical Research Re-Launches ResearchTrials.orgClinical research company, Probity Medical Research Inc. (PMR), re-launched ResearchTrials.org, the online portal to connect patients with medical researchers in Canada, the US and Australia. Probity Medical Research Expands Clinical Trial Operations to AustraliaProbity Medical Research Inc. (PMR) a leading provider of clinical research support services has expanded clinical research activity by launching operations in Australia... |
|
![]()
Each clinical research site is independently owned and operated by specialists who run large community based practices.
Learn more.
Copyright 2011 Probity Medical Research Inc. All Rights Reserved.